Correct temporal and spatial control of actin dynamics is essential for the cytotoxic T cell effector function against tumor cells. However, little is known whether actin engineering in tumor-targeted T cells can enhance their antitumor responses, thereby potentiating the adoptive T cell therapy. Here, we report that TAGLN2, a 22-KDa actin-stabilizing protein which is physically associated with lymphocyte function-associated antigen-1 (LFA-1), potentiates the OTI TCR CD8 + T cells to kill the intercellular adhesion molecule-1 (ICAM-1)-positive/OVA-presenting E0771 cells, but not ICAM-1-negative OVA-B16F10 cells, suggesting an 'inside-out' activation of LFA-1, which causes more efficient immunological synapse formation between T cells and tumor cells. Notably, recombinant TAGLN2 fused with the protein transduction domain (TG2P) overcame the disadvantages of viral gene delivery, leading to a significant reduction in tumor growth in mice. TG2P also potentiated the CD19-targeted, chimeric antigen receptor (CAR)-modified T cells to kill Raji B-lymphoma cells. Our findings indicate that activating the TAGLN2-actin-LFA-1 axis is an effective strategy to potentiate the adoptive T-cell immunotherapy.
Introduction
Cancer immunotherapies have led to important clinical advancements and provided new tools for the management of cancer. One emerging approach for cancer immunotherapy is the reactivation of tumor-infiltrated lymphocytes (TILs) by targeting checkpoint proteins, such as programmed death-1 (PD-1) or cytotoxic T lymphocyte antigen 4 (CTLA4). 1 However, the response rates are not sufficient. 2, 3 Another approach involves the use of chimeric antigen receptor (CAR)-engineered T or natural killer (NK) cells into 'cancer hunter cells'. 4 However, these approaches have not yet been transferred to solid tumors, due in part to the strong immunosuppressive tumor microenvironment that may protect them from immune attack. [5] [6] [7] It is therefore of great clinical interest to develop new strategies to potentiate the antitumor activities of reactivated TILs or CAR-engineered T and NK cells.
The immunological synapse (IS) is a multi-molecule functional structure that forms at the interface between a T cell and an antigen-presenting cell (APC) expressing the appropriate peptide/MHC complexes. 8 Subsequent studies have revealed relevant ISs between different types of immune cells and between immune cells and nonimmune cells, including tumor target cells. 9 During IS formation, T-cell antigen receptors (TCRs) constitute the main supramolecular activation clusters (c-SMACs) and elicit the "competence" signal for cellular activation. 8 However, full activation of T cells requires costimulatory "progression" signals resulting from the interaction of accessory receptors, e.g., CD2 10 or CD28, 11, 12 with their natural ligands, CD58 or CD80/86, respectively. Interestingly, cumulative evidence has suggested that although TCR stimulation results in actin polymerization, costimulatory signals lead to stronger, large-scale actin responses, which constitute the outermost distal-SMAC (d-SMAC) of the IS and promote the accumulation of receptors to the c-SMAC by retrograde actin flow, thereby resulting in full T-cell activation. 12, 13 However, suppression of costimulatory signals exploited by tumors may attenuate the actin rearrangement at the IS. Consequently, the absence of costimulation leads to a state of unresponsiveness/anergy or even cell death through apoptosis. 11 Actin cytoskeletons are also associated with integrin leukocyte function-associated antigen-1 (LFA-1) via cytoplasmic adaptor proteins, such as talin and vinculin, and regulates LFA-1 activity through avidity changes.
14 These growing evidences have suggested that controlling the actin cytoskeleton at the IS will open a new way to be overcome the insufficient costimulatory signals under strong immunosuppressive conditions at tumor sites. Therefore, we hypothesized that engineering of local actin dynamics at the IS will get over the current limits of immunotherapies adopting checkpoint blockades or engineered CAR-T cells by taking complete advantage of their efficacy.
Transgelin (TAGLN) is a small 22-kDa actin-binding protein that was first discovered in chicken gizzard smooth muscle 15 and was originally designated "transgelin" because of its transformation-sensitive and rapid actin-gelling properties. 16 Among three TAGLN superfamily members, we recently reported that TAGLN2 is predominantly expressed in T cells and stabilizes cortical F-actin to maintain the IS. 17 We also found that TAGLN2 overexpression caused LFA-1 activation after TCR stimulation. 17 In the present study, we found that TAGLN2 physically associated with LFA-1 via its calponin homology (CH) domain and enhanced the activity of Rap1, a small GTPase that has been shown to regulate LFA-1 affinity and clustering. [18] [19] [20] This biochemical property of TAGLN2 may have several advantages when applied to cancer immunotherapy. First, direct engineering of the integrin ectodomain can result in serious off-target effects because effector cells can also bind to unwanted cells or tissues that express intracellular adhesion molecules (ICAMs). Activation of LFA-1 by "inside-out" signaling will minimize deleterious off-target effects. Second, because LFA-1 functions as a homing receptor for leukocyte migration and diapedesis, increased avidity of LFA-1 by TAGLN2 may facilitate effector cell migration to the tumor areas. Third, increased filamentous (F)-actin contents at the IS can mimic full activation signals as evoked by costimulatory receptorligand interactions, although strong suppressive microenvironments are dominant. Fourth, stable IS formation between effector killer cells and tumor target cells can increase the rate of tumor cytotoxicity.
In the current work, to our surprise, we observed that CD4 + and CD8 + T cells from severe tumor-bearing mice show significant reduction of TAGLN2 expression, suggesting an impaired T cell adhesion to APCs or tumor cells via LFA-1. We therefore evaluated the efficacy of TAGLN2 overexpression in cytotoxic OTI TCR T cells targeting two selected OVA-peptide presenting tumors, i.e., E0771 breast tumor and B16F10 melanoma. Since virus-based gene delivery systems have many disadvantages, including cost and safety issues. 21 We developed a protein transduction domain (PTD)-linked recombinant TAGLN2 (TG2P) and applied for both mouse OTI CD8 + T cells and human CD19-targeted, chimeric antigen receptor (CAR)-modified T cells. We expect that TG2P may be widely applicable for many types of adoptive cell-mediated cancer immunotherapies.
Results

TAGLN2 stabilizes immunological synapse by
Previously, we found that TAGLN2 (TG2), which is predominantly expressed in lymphocytes, is highly concentrated at the peripheral actin ring of the IS (Figure 1(a) ) and corresponds to increased F-actin contents (Figure 1(b) ) and T-APC conjugate formation (Figure 1(c)) . 17 In the present study, we also found that TAGLN2 was physically associated with LFA-1 through its CH domain, regardless of stimulation (Figure 1(d,e) ), and corresponded to the activation of Rap1 (Figure 1(f) ), which functions as a key regulator of LFA-1-dependent adhesion and migration of T cells. [18] [19] [20] These results suggested that TAGLN2, in addition to its biochemical characteristics enabling it to control actin dynamics, acted as a cytosolic factor to modulate 'inside-out' signaling of the integrin LFA-1. The schematic diagram in Supplemental Figure 1 indicates the potential mechanisms of action of TAGLN2 in T cells. TAGLN2 not only stabilized F-actin but also blocked cofilin-mediated actin polymerization, resulting in increased F-actin contents at the IS 17 and leading to prolonged T-cell activation and IL-2 production. Additionally, TAGLN2 regulated 'inside-out' integrin LFA-1 function when T cells received a primary antigen signal through the TCR, even though the 'outside-in' costimulatory signals were weak in the tumor microenvironment. This led to the stable adhesion of T cells to the tumor target cells. These dual regulatory mechanisms of TAGLN2 enhanced T-cell activation, leading us to hypothesize that TAGLN2 could be a potential effector molecule with the ability to potentiate cancer cell killing via cell therapies. Thus, TAGLN2 may be applicable in many types of cancer immunotherapies, including CAR or TCR transgene-adopted cytotoxic T cells and NK cells. Strikingly, we further found that CD4 + or CD8 + T cells from severe E0771 tumor-bearing mice showed significant reduction of TAGLN2 levels ( Figure 1(g) ), strongly suggesting that T cells from tumor-bearing mice may have an impaired adhesion capacity mediated by LFA-1/ICAM-1 interaction. This result further urged us to investigate whether TAGLN2 acts as a potential T-cell booster that potentiates the antitumor response of cytotoxic T effector cells against ICAM-1-positive cancer cells.
Retroviral transduction of TAGLN2 potentiated the cytotoxicity of OTI CD8
+ T cells against icam-1-positive cancer cells and enhanced T-cell adhesion and cytokine release Next, we generated a retroviral DNA construct containing wild-type TAGLN2 and eGFP genes or eGFP (empty vector [EV]) alone (Figure 2(a) ). Retroviral particles containing TAGLN2 or EV were then produced from host plat E cells and infected into mouse primary CD8 + T cells for determination of the viral transduction efficiency by flow cytometry. The efficiency was generally over 80% (Figure 2(b) ) and was also confirmed by western blotting (Figure 2(c) ). Next, we questioned whether TAGLN2 expression may influence CD8 + T cell adhesion to cancer cells via the LFA-1/ICAM-1 interaction, as we observed for T-cell conjugation with APCs ( Figure 1(c) ). To this end, we examined the expression levels of ICAM-1 in two cancer cell lines. Interestingly, B16F10 melanoma expressed little ICAM-1, whereas E0771 breast cancer cells expressed relatively high amounts of ICAM-1 (Figure 2(d) ). By performing conjugation assays, we observed that OTI TCR  + CD8  + T cells overexpressing TG2 (OTI TG2-CD8 + T cells) showed significant increases in the numbers of conjugates when the cells were incubated with OVA257-264 peptide-loaded E0771 (OVA-E0771) cells, but not with OVAloaded B16F10 (OVA-B16F10) cells (Figure 2 (e) and Figure S2 ), suggesting that the costimulatory LFA-1/ ICAM-1 interaction was critical for cytotoxic T-cell adhesion to ICAM-1 + cancer target cells. This conclusion was further corroborated by utilizing anti-LFA-1 antibodies; anti-LFA-1, but not control IgG, antibodies significantly reduced the number of conjugates between TG2-CD8 + T cells and E0771 cells (Figure 2(e) ).
We next questioned whether the strong conjugation of OTI TG2-CD8 + T cells with E0771 cells was correlated with increased cytokine release and cytotoxicity. mGranzyme B (mGZMB) was significantly elevated in the population of OTI TG2-CD8 + T cells interacting with OVA-E0771 cells (Figure 2(f) ). Furthermore, these cells significantly lysed E0771 cells, but not B16F10 cells (Figure 2(g) ). These data indicated that overexpression of TG2 influenced the ability of OTI CD8 + T cells to effectively kill tumor cells, presumably by upregulating actin-dependent signaling pathways and promoting costimulatory LFA-1 activation.
Retroviral transduction of TAGLN2 potentiated the antitumor activity of OTI CD8 + T cells in vivo
Since our in vitro data revealed that OTI TG2-CD8 + T cells showed increased conjugation with target cancer cells together with enhanced cytokine release and higher cytotoxicity, we then examined the effectiveness of OTI TG2-CD8 + T cells in vivo. To this end, OVA-E0771 cells were implanted into the mammary fat pads of C57BL/6 female mice. Fourteen days later, the mice were injected intravenously with OTI EV-CD8 + T and/or OTI TG2-CD8 + T cells (Figure 3(a) ). Two days later, the mice were sacrificed, and cancerous tissues were removed. Cryosection of the removed cancer tissues showed that both OTI EV-CD8 + T and OTI TG2-CD8 + T cells were similarly targeted to tumors originating from E0771 cells, as determined by confocal and fluorescence-assisted cell sorting (FACS) analyses (Figure 3(b) ). We used immunohistochemistry to determine the expression levels of several proteins and the number of apoptotic cells in the tumor sites and found that cells positive for mKi67, a cancer cell proliferation marker, were decreased, whereas cells positive for interferon gamma (mIFNγ), mGZMB, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining were significantly increased in tumor sites injected with the OTI TG2-CD8 + T compared with OTI EV-CD8 + T cells (Figure 3(c) ). For all the three groups, the cellular morphologies (H&E) and the expression levels of ICAM-1 in tumor sites were not significantly different (Figure 3(d) ). Similar to Figure 3(b) , the numbers of tumor-infiltrated CD8 + T cells were similar in the OTI EV-CD8 + T and OTI TG2-CD8 + T groups, but higher in the non-treated group (Figure 3(d) ).
To evaluate the effects of OTI TG2-CD8 + T cells on tumor growth in vivo, OVA-E0771 cells were implanted into the mammary fat pads of C57BL/6 mice. Seven days later, the mice were randomized into three groups for administration of OTI CD8 + T cells. OTI EV-CD8 + T or OTI TG2-CD8 + T cells were injected intravenously three times at 3-day intervals (Figure 3(e) ). All animals were sacrificed 28 days after tumor injection, and the tumors were weighed. The average tumor weight from mice injected with OTI EV-CD8 + T cells was lower than that of tumors without cell injection, suggesting that adoptive cytotoxic T-cell transfer efficiently reduced tumor growth in vivo. Interestingly, intravenous administration of OTI TG2-CD8 + T cells significantly reduced tumor size compared with that of tumors without adoptive cell transfer or tumors transferred with OTI EV-CD8 + T cells (Figure 3(f,g) ). Kaplan-Meier survival studies 40 days after tumor injection showed that untreated mice and mice receiving non-transduced T cells had median survival times of 35 and 43 days, respectively. In contrast, mice adoptively transferred with OTI TG2-CD8 + T cells had an 85% probability of surviving longer than 45 days (Figure 3(h) ).
Recombinant TAGLN2 fused with PTD (TG2P) was efficiently internalized into T cells and enhanced T-cell adhesion and cytokine release Small protein domains, commonly referred to as PTDs, have been developed for the delivery of certain therapeutic macromolecules into eukaryotic cells. 22 To overcome the disadvantages of virus-mediated gene delivery systems, such as inconsistent transduction efficiency, long-term preparation, high cost, and safety issues, we generated TAGLN recombinant protein fused with PTD (TG2P), which was easier and faster to transduce into mouse primary T cells (Figure 4(a) ). Only TG2 containing PTD (TG2P and TG2P (-LPS)) were readily internalized into the T cells (Figure 4(b,c) ), and internalized TG2P was as stable as endogenous TAGLN2 for at least 24 h (Figure 4(d) ).
We next determined whether treatment with TG2P showed the same efficacy as viral transduction of TAGLN2 in terms of CD3 + T cell adhesion to antigen-loaded B cells. We found that CD3 + T cells treated with TG2P (TG2P-CD3 + T cells) significantly increased the number of conjugates when cells were incubated with SEB-loaded B cells. The number of conjugates was correlated with the concentration of TG2P used to treat T cells + or CD8 + T cells from normal or severe tumor-bearing mice. When tumor size of the mice was over 3,000 mm 3 , the mice were defined as "severe tumor-bearing mice". CD4
+ or CD8 + T cells were purified from spleen and lymph nodes of mice and then subjected to western blot analysis. Intensities of western blot bands were analyzed by the Quantity one image analysis program (Bio-Rad) and were normalized to β-actin. *P < 0.05. We further evaluated the effects of OTI TG2P-CD8 + T cells on tumor growth in vivo. OTI TG2P-CD8 + T cells significantly reduced the average tumor weight compared with that of tumors without adoptive cell transfer or treated with OTI CD8 + T cells without TG2P, suggesting that recombinant TG2P had effects similar to those of retrovirus-based gene delivery ( Figure 7(d,e) ). Kaplan-Meier survival studies showed that untreated mice and mice treated with non-transduced OTI T cells had a median survival of 36 and 48 days, respectively. In contrast, mice adoptively transferred with OTI TG2P-CD8 + T cells had a 100% probability of surviving more than 50 days (Figure 7(f) ).
Human CD19-targeted CAR-T cells with TG2P showed enhanced the antitumor activity against Raji B-lymphoma cells
To investigate whether TG2P is also useful for CAR-modified T cells, human CD19-targeted CAR-T cells were treated with TG2P, and then the cells were incubated CD19 + Raji B-lymphoma cells. TG2P treatment significantly increased the number of CAR-T-B-lymphoma conjugates ( Figure 8(a) ). Consistently, it augmented the CAR-T-mediated cytotoxic activity more than 2-folds (from 9.24 to 21.15%) (Figure 8(b) ). Cytokine analysis revealed that TG2P significantly increased IFN-γ and granzyme B release from CD19-engaged CAR-T cells (Figure 8(c)) . These results strongly demonstrate that TG2P could be a promising protein drug that is useful for all kinds of adoptive T cell therapies.
Discussion
To date, it is unclear whether controlling actin dynamics at the IS exerts positive effects on cell-mediated cancer immunotherapy. Furthermore, the effectiveness of modulation of integrin 'inside-out' signaling in cell therapy has not yet been proven. In the present study, we obtained strong evidence showing that overexpression of TAGLN2, a 22-kDa small actin stabilizing protein predominantly expressed in lymphocytes, in primary cytotoxic T cells significantly enhanced tumor cytotoxicity via increased stabilization of the IS between cytotoxic T cells and tumor target cells in vitro. The efficacy was largely dependent on the expression of ICAM-1 on tumor target cells, suggesting that regulation of LFA-1 activity by TAGLN2 via actin stabilization was critical for T cell-mediated anticancer activity. Viral transduction of TAGLN2 in cytotoxic OTI CD8 + T cells effectively suppressed tumor growth in vivo as compared with OTI CD8 + T cells containing EV. These findings suggested that stabilization of F-actin by TAGLN2 and the resulting LFA-1 avidity change at the IS was an effective strategy for cytotoxic CD8 + T cell-mediated cancer immunotherapy. Furthermore, we found that PTD-fused recombinant TAGLN2 had strong potential to be developed as an active adjuvant in cancer cell therapy due to its effectiveness and easy loading on various types of tumor-specific killer cells including CAR-modified human T cells.
Dynamic rearrangement of the actin cytoskeleton at the IS is absolutely necessary to sustain correct temporal and spatial control of the T-cell activation process. 13, 23 TCR stimulation results in actin polymerization. 24 For full activation, however, T cells also require 'outside-in' costimulation, which leads to significant rearrangement of the actin cytoskeleton and promotes accumulation of receptors and raft membrane microdomains at the interface between T cells and APCs. [10] [11] [12] 25 These previous works imply that the artificial engineering of F-actin contents at the IS may mimic the signals evoked by costimulatory molecules. From this perspective, we utilized TAGLN2 as we found in a previous report that TAGLN2 increases F-actin contents through stabilization of F-actin in T cells during IS formation. 17 Recently, we also found that TAGLN2 is significantly upregulated in macrophages in response to lipopolysaccharide and enhances macrophage phagocytic function, 26 demonstrating that TAGLN2 plays an essential role in actin dynamics at the immunological or phagocytic synapses. In the present study, more strikingly, drastic down-regulation of TAGLN2 in T cells from severe E0771 tumor-bearing mice further emphasizes that TAGLN2 is an important actin regulator for cytotoxic T cell adhesion to tumor target cells. However, other proteins also can be considered. For instance, L-plastin, similar to TAGLN2, stabilizes actin filaments by means of its actin-bundling activity. 27 In contrast, cofilin enhances actin polymerization via its actinsevering activity. 28 Interestingly, we previously showed that TAGLN2 and cofilin localize to two distinguishable regions in the IS; cofilin localizes to the upper region of d-SMAC, where TAGLN2 is rather absent, and TAGLN2 localizes at the bottom of d-SMAC. 17 We found that TAGLN2 was physically associated with LFA-1 via the CH domain. TAGLNs belong to the calponin family and contain a single CH domain. 29 However, the CH domain alone does not mediate actin binding. 29 We, therefore, suggest that the CH domain of TAGLN2 may mediate the physical connection between F-actin and the cytoplasmic domain of LFA-1, thereby directly transmitting the inside actin-related signals to LFA-1 and eventually resulting in increased LFA-1 avidity. Consistent with this, significant activation of the small GTPase Rap1 in T cells overexpressing TAGLN2 suggested that TAGLN2, together with vinculin, talin, and RapL, is a protein contained in the cytoplasmic signalosomes of LFA-1. 30 These data further suggested that TAGLN2 directly controls LFA-1 avidity rather than indirectly controls it by upregulation of actin contents.
The cell adhesion molecules LFA-1 (CD11a/CD18) and ICAM-1 (CD54) are required for T-cell infiltration into tumors and antitumor function. 31 Indeed, administration of anti-LFA-1 antibodies completely abrogates the efficacy of adoptive immunotherapy, 32 suggesting an important contribution of LFA-1 in tumor immunology. However, no modulators that increase the affinity of LFA-1 have been applied to antitumor activity because they may have deleterious effects as a result of unwanted binding of T cells to non-target, ICAMpositive cells or tissues. Thus, it is theoretically reasonable to consider a strategy that controls the inside-out activation of LFA-1 by manipulating signals involved in the pathways of LFA-1 activation. In this regard, full-activation of LFA-1 through TCR-mediated, actin-linked strategies will be useful for cell therapies that are based on the recognition of tumorassociated antigen signals via TCRs or CARs. Indeed, although LFA-1 itself is not specific for tumor cells, it can be tumor-specific as it is only activated after TCRs or CARs are engaged with tumor antigens.
One major concern of the results of the current study is whether the overexpression of TAGLN2 in T cells may nonspecifically affect other non-tumor cells expressing ICAM-1 in vivo. Indeed, we observed that TAGLN2 overexpression alone slightly increased F-actin contents as well as Rap1 activity in T cells, resulting in a slight increase in the conjugation between T cells and tumor target cells even in the absence of antigen peptides. However, in the absence of a tumor antigen, the slight increase in adhesion seemed to have no direct effect on T-cell-mediated cytotoxicity in vivo as the CD8 + T cells were not activated. In addition, it is generally accepted that the actin cytoskeleton regulates LFA-1 ligand binding through avidity rather than affinity changes. 33 In contrast, TCR signals stimulate the adhesiveness of LFA-1 through both affinity and avidity regulations. 34 It has been shown that genetically engineered T cells with affinity-enhancing LFA-1 mutation show perturbed intravascular crawling to transmigration sites, thereby compromising diapedesis across the blood vessels. 35 In our case, however, overexpression of TAGLN2 did not affect the migration of OTI CD8 + T cells into the tumor sites, suggesting that LFA-1 avidity regulation does not influence T-cell diapedesis across the tumor blood vessels. Moreover, we found that tumor non-specific polyclonal TG2P-CD8 + T cells have little effect on tumor suppression (data not shown), suggesting that the TAGLN2-actin-LFA-1 axis can be effective when T cells are activated via TCRs or CARs. ICAM-1 is expressed in APCs and, as a major ligand of LFA-1, is also expressed in several tumors. 31, [36] [37] [38] Consistent with this, transfection of ICAM-1 into colorectal cancer cell lines inhibits tumor growth and metastasis. 39 In addition, the production of prostaglandin E2 in the tumor microenvironment downregulates the expression of ICAM-1 in tumor cells, reducing the cytotoxic effects of T cells. 40 Thus, ICAM-1 could be a potential . The above cells in (a) were further incubated for 6 h, and E0771 cell (1 × 10 6 ) death (cytotoxicity) was then assessed by LDH release. (c) Cytokine analysis. Secreted cytokines (mIL-2, mIFNγ, and mGZMB) were measured by ELISAs (6 h). Data represent the means of three experiments ± SDs. *P < 0.05 versus OTI non-CD8 + T cells.
target for cancer immunotherapy. However, in some reports, the expression of ICAM-1 has been shown to be positively correlated with a more aggressive tumor phenotype and metastatic potential, 38, 41 suggesting that ICAM-1 is not a good primary target protein for cancer immunotherapy. However, as shown in the present study, ICAM-1 could play an important role as an adhesion site for cytotoxic killer T cells. However, a problem of targeting ICAM-1 on cancer cells is that not all cancer cells express ICAM-1 on their surfaces. In this study, however, we found that although OTI TG2 (or TG2P)-CD8 T cells were ineffective for killing B16F10 melanoma cells in vitro, adoptive transfer of these cells significantly suppressed the tumor growth of B16F10 cells in vivo (data not shown). Interestingly, we found that ICAM-1 was induced in B16F10 tumor cells in vivo, presumably due to the production of cytokines, such as IFNγ and IFNβ, in the tumor microenvironment. Indeed, B16F10 cells have been shown to express ICAM-1 in response to IFNγ and IFNβ treatment. 42 Moreover, IFNγ-primed and IFNβ-treated B16F10 cell vaccines enhance CTL responses to melanoma cells in vivo. 42 Therefore, further studies are underway to determine whether co-immunotherapy with IFNγ and TG2-CD8 + T cells can improve the outcomes of ICAM-1-negative tumor cells. The discovery of PTDs and cell-penetrating peptides (CPPs) in the late 1980s established a basis for further studies of the cellular delivery of large, bioactive molecules. 22 PTDs are now widely used as research tools and applied for the delivery of macromolecular drugs in patients with a variety of diseases. 22, 43 PTDs have also been developed for cancer treatment, including treatment of preclinical tumor-bearing animals. 43 Although it is still too early to predict the outcomes of clinical trials, there have been more than 20 phase I and phase II clinical trials performed by biotech companies and academic institutions. 22 Notably, no adverse effects of PTD-mediated delivery have been reported, thereby suggesting that PTD-mediated delivery is safe for patients. To the best of our knowledge, however, no reports have described the use of PTDs or CPPs directly enhancing cytotoxic T-cell functions in vitro and applying these PTDs or CPPs to kill tumor target cells in vivo. This approach will overcome many issues of PTD-conjugated drugs when applied systemically. As described above, PTD-based approaches also overcome the disadvantages of virus-based gene delivery, including inconstant transduction efficiency, time-consuming protocols, high cost, and safety issues. One of the downsides of the PTD-based approach for cell therapy is that it is not as stable as virus-based gene expression. However, the results presented here demonstrate that TG2P is as stable as endogenous TAGLN2 at least for 24 h. In addition, the fact that TG2P did not differ from the virus-mediated gene delivery system in terms of its efficacy implies that cytotoxic CD8 + T cells may exert their activity at the early period of adoptive cell transfer; otherwise, this disadvantage has a positive aspect as it can minimize the off-target effects caused by the unnecessary long-term activity.
In conclusion, two major approaches of immunotherapies have led to a new era in cancer treatment. Checkpoint blockade can circumvent the natural inhibitory signals that limit T-cell effector function. 2 Simultaneously, cell-based immunotherapy has emerged as a highly promising approach for the treatment of cancer. 5 However, both strategies have limitations, including a lack of responsive in some patients, 2 difficulty in treating solid tumors, 4 and off-target toxicities. 1, 4, 7, 44 Therefore, it is of great clinical interest to develop alternative methods to potentiate cancer cell therapy. Accordingly, actin and integrin control by TAGLN2 may be used in combination with currently available cytotoxic T cell-and NK cell-mediated therapies.
Materials and methods
Reagents and antibodies
Rabbit polyclonal anti-TAGLN2 antibodies were raised in rabbits using purified full-length TAGLN2 (AbFrontier, Seoul, Korea). Rabbit polyclonal anti-green fluorescent protein (GFP) and rabbit polyclonal anti-β-actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). ) for 6 and 24 h. Secreted cytokines (IL-2, IFNγ, and GZMB) were measured by ELISAs (24 h). mRNA levels were determined by qRT-PCR (6 h). Data represent the means of three experiments (a-c) ± SDs. *P < 0.05 versus EV-CD8 + T cells.
(Invitrogen) into HEK293T cells. After 48 h, the supernatants were collected and spin infected into B16F10 cells by centrifugation at 800 × g for 30 min in the presence of 8 μg/ml polybrene. Naïve CD3 + T cells were purified from mouse spleen and lymph nodes by negative selection using a T-cell enrichment column (R&D Systems). To generate mouse T-cell blasts, CD3 + T cells were incubated in 2 µg/mL anti-CD3/28 coated culture plates with 100 U/mL rIL-2 for 48 h and cultured for an additional 5 days with 100 U/mL rIL-2. Mouse splenocytes were dispersed and purified into CD4 + , CD8 + and CD19 + populations using EasySep (StemCell Technologies, Seattle, WA). The purity of each population was confirmed to be more than 95% by flow cytometry.
cDNA constructs
To generate TAGLN2 constructs, a TAGLN2 clone coding for the full-length open reading frame was purchased from ImaGene (Berlin, Germany). TAGLN2, TAGLN2ΔCR (Δ174-199), TAGLN2ΔCH (Δ2-136), and TAGLN2ΔAB (Δ153-160) genes were generated by standard or overlapping PCR and subcloned into the pEGFP vector (Addgene). To produce Histagged TG2P, the pET-21a vector was used as an expression vector; this vector has a T7 promoter and provides six His residues at the C terminus of the expressed protein. The coding sequence of TAGLN2 was amplified by PCR, and the products were incorporated into the pET-21a vector (Novagen, Madison, WI). The mouse ICAM-1 coding sequence region was ligated to pHJ-1 as a lentiviral vector (CMV promoter).
Animals
C57BL/6 wild-type mice and OTI TCR transgenic mice (C57BL/6 background) were purchased from Jackson Laboratories (Bar Harbor, ME). All mice were housed in specific pathogen-free conditions. All experimental methods and protocols were approved by the Institutional Animal Care and Use Committee of the School of Life Sciences, Gwangju Institute of Science and Technology and carried out in accordance with their approved guidelines.
Reverse transcription PCR (RT-PCR) and real-time quantitative RT-PCR (qRT-PCR)
Total RNA was isolated from cells using TRIzol reagent (Molecular Research Center, Cincinnati, OH). cDNA was prepared using RT Premix. Real-time qPCR was conducted in an ABI PRISM 7300 RT-PCR System using a SYBR Green PCR Master Mix (Applied Biosystems, Carlsbad, CA) and gene-specific primers (forward and reverse pairs, respectively) as follows: mouse IL-2, 5′-CACGTCTTGCACTTGTCAC-3′ and 5′-CCTTCTTGGGCATGTAAAACT-3′; mouse INFγ, 5′-GCTCTGAGACAATGAACGCT-3′ and 5′-AAAGAGATAAT CTGGCTCTG-3′; mouse GZMB, 5′-TTTCATCCTGTAATT GGACTAA-3′ and 5′-GCGATCTCCACACTTCTC-3′; mouse GAPDH, 5′-GCACAGTCAAGGCCGAGAAT-3′ and 5′-GCCTTCTCCATGGTGGTGAA-3′; human IL-2, 5′-TGTCA CAAACAGTGCACCTAC-3′ and 5′-CAGTTCTGTGGCCTT CTTGG-3′; human IFNγ, 5′-GAGTGTGGAGACCATCAA GGA-3′ and 5′-CGACAGTTCAGCCATCACTT-3′; human GZMB, 5′-AGGCTACCTAGCAACAAGGC-3′ and 5′-TCG ATCTTCCTGCACTGTCA-3′; human GAPDH, 5′-ACCCA GAAGACTGTGGATGG-3′ and 5′-TCAGCTCAGGGATGA CCTTG-3′. The mRNA levels of the target genes relative to GAPDH were normalized using the following formula: relative mRNA expression = 2 − ( ΔCt of target gene -ΔCt of GAPDH ), where Ct is the threshold cycle value. In each sample, the expression of the analyzed gene was normalized to that of GAPDH and described as the mRNA level relative to GAPDH.
Retroviral transduction in mouse T cells
Before retroviral transduction, mouse CD3 + T cells from C57BL/6 mice or CD8 + T cells from OTI TCR C57BL/6 mice were incubated in 2 μg/mL anti-CD3/28-coated plates with 100 U/mL rIL-2 for 48 h. A total of 5 × 10 6 retroviral packaging cells (Plat-E; Cell Biolabs) were plated overnight in 10-cm 2 dishes. Retroviral particles were generated by transfection with retroviral vectors (empty vector, GFP, and TG2) and pCL-Eco packaging vector using Lipofectamine 2000 (Invitrogen). After 48 h, virus supernatants (1 mL) were harvested, mixed with 10 6 mouse T cells, incubated in 12-well plates coated with 20 μg/mL retronectin (Takara, Otsu, Japan), and centrifuged for 90 min at 2,000 × g at 25°C with 100 U/mL rIL-2. The transduced T cells were maintained with fresh media with rIL-2 and expanded for 5-8 days.
Purification of TG2P
Expression of TG2P in Escherichia coli BL21 (DE3) cells was performed as described for transformation of the aforementioned recombinant plasmids. Expression of TG2P was induced by addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside to the culture medium overnight at 25°C, and cells were then collected. The cell pellets were resuspended in PBS, sonicated, and centrifuged. After centrifugation, TG2P in the supernatant was purified by affinity chromatography on a His-selected Nickel Affinity Gel (Sigma). The gel was equilibrated with 10 volumes of buffer (50 mM sodium phosphate, pH 8.0 and 0.3 M NaCl) and incubated with the supernatant. The gel was washed with five volumes of wash buffer (50 mM sodium phosphate, pH 8.0, 0.3 M NaCl, and 10 mM imidazole). The TG2P was eluted with increasing concentrations of imidazole up to 250 mM. To remove potential endotoxin contaminants, TG2P was further subjected to the polymyxin B-agarose (Detoxi Gel, Thermo Scientific Inc.) column. Briefly, polymyxin B-agarose column was washed with five volumes of 1% sodium deoxycholate followed by ten volumes of PBS. The eluted TG2P was loaded onto the column and incubated at room temperature for 1 h. The column was then eluted with PBS. TG2P was desalted using PD-10 Sephadex G-25 (Amersham Pharmacia Biotech, Uppsala, Sweden), supplemented with 10% glycerol, separated into aliquots, and flash-frozen at −70°C.
Introduction of TG2P into the cytotoxic CD8 + T cell blasts T cells were washed and incubated with indicated concentration (1, 2.5, 5, and 10 μM) of TG2P for 4 h at 37°C in serumfree medium. After incubation, the cells were washed in PBS and then resuspended in media.
Determination of cellular F-actin contents
Cells were maintained in serum-free medium for 12 h and incubated with anti-CD3/28 for the indicated times at 37°C. The reactions were terminated by adding 4% paraformaldehyde. Fixed cells were washed once with phosphate-buffered saline (PBS) and resuspended in PBS containing 1% bovine serum albumin and 0.25% Triton X-100 for 5 min. After permeabilization, cells were washed, stained for 30 min with TRITC-phalloidin (Sigma), and then analyzed by flow cytometry. 
Confocal microscopy
To investigate TAGLN2 localization, Jurkat T cells expressing TG2_GFP were transfected with LifeA_RFP and incubated for 30 min with 1 μg/mL SEE-pulsed Raji B cells stained with ICAM-1_Cy5. The cells were then placed on PLL-coated glass and imaged using a 100×, NA 1.40 oil immersion objective on a laser-scanning confocal microscope (FV1000; Olympus, Tokyo, Japan). To evaluate ICAM-1 expression in B16F10 and E0771 cells, cells were detached using 10 mM ethylenediaminetetraacetic acid, stained with anti-ICAM-1-FITC, and observed using a 60×, NA 1.40 oil immersion objective. In some conjugation assays, samples were prepared as described above, and E0771 (5 × 10 ) were stained with CMFDA-green and incubated with cancer cells for 2 h. The unattached cells were removed by washing with warm PBS and observed using a 40×, NA 1.40 oil immersion objective.
Western blotting
Cells were lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 1% Triton X-100, and one tablet of complete protease inhibitors) for 15 min on ice. Cell lysates were centrifuged at 16,000 × g for 30 min at 4°C
, and the supernatants were eluted with sodium dodecyl sulfate (SDS) sample buffer (100 mM Tris-HCl, pH 6.8, 4% SDS, and 20% glycerol with bromophenol blue) and heated for 5 min. The proteins were separated by SDS polyacrylamide gel electrophoresis (PAGE) on 10-15% gels and were transferred to nitrocellulose membranes using a Trans-Blot SD semidry transfer cell (Bio-Rad). The membrane was blocked in 5% skim milk (1 h), rinsed, and incubated with the appropriate antibodies in TBS containing 0.1% Tween 20 (TBS-T) and 0.5% skim milk overnight. Excess primary antibody was then removed by washing the membrane three times in TBST. The membrane was then incubated with 0.1 μg/mL peroxidase-conjugated secondary antibodies (antirabbit or anti-mouse) for 1 h. After three washes with TBST, bands were visualized using western blotting detection reagents and were then exposed to X-ray film (Kodak, Rochester, NY).
Immunoprecipitation (IP)
Cell lysates were precleared, and supernatants were incubated overnight with antibodies at 4°C, followed by incubation with protein A/G agarose beads (Santa Cruz Biotechnology). Beads were collected, washed with PBS, and resuspended in equal volumes of 5× SDS loading buffer. Immunoprecipitated proteins were separated by SDS-PAGE on 12% gels and analyzed by western blotting, as described above.
Pull-down assay for active Rap1
Active GTP-bound Rap1 levels were measured using an EZDetect Rho activation kit according to the manufacturer's instructions (Thermo Fisher Scientific Inc., Rockford, IL). Briefly, Jurkat T cells expressing GFP or TG2_GFP cells were stimulated with anti-CD3/28 for the indicated times at 37°C, washed once with ice-cold PBS, and lysed in buffer containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail. Samples were incubated on ice for 20 min followed by centrifugation (16,000 × g, 30 min, 4°C). Equivalent amounts of supernatants were incubated with GST-RalGDS-RBD/GSH-beads for GTPRap1 for 12 h at 4°C. The beads were washed three times with lysis buffer, and bound proteins were eluted with sample buffer by boiling. Samples were electrophoresed and analyzed by western blotting with anti-Rap1 antibodies.
Flow cytometric analysis
Cells were suspended in PBS containing 2% FBS and stained with fluorescence-conjugated antibodies against mouse ICAM-1 or isotype control for 15 min at room temperature. Cells were then assessed on a FACSCanto instrument (BD Biosciences), and the data were analyzed with FlowJo software (Treestar).
Measurement of cytokine secretion
CD3
+ T (1 × 10 6 ) or OTI CD8 + T cells (1 × 10 6 -1 × 10 7 ) were stimulated with SEB-loaded B cells (1 × 10 6 ) or OVAloaded cancer cells (1 × 10 6 ). Human CD8 + T or CD19-targeted CAR-T cells (5 × 10 6 ) were incubated with Raji B cells (1 × 10 6 ). After incubation for the indicated time points, the amounts of mouse of human IL-2, IFNγ, and GZMB in the supernatants were determined by ELISA with Duo Set Mouse ELISA kits (R&D Systems).
In vitro cytotoxicity assay
For in vitro cytotoxic T-cell activity assays, OTI CD8 + T cells (1 × 10 6 -1 × 10 7 ) were generated and incubated with E0771 or B16F10 cells (1 × 10 6 ) in the absence or presence of OVA. After 6 or 24 h, cell-mediated cytotoxicity was determined using a Pierce LDH Cytotoxicity Assay Kit (Thermo Scientific Inc.), and the percent cytotoxicity was calculated according to the manufacturer's instructions. For flow cytometric cytotoxicity assays, PKH26 (Sigma) was diluted according to the manufacturer's kit directions. E0771, B16F10, or Raji B cells (1 × 10 6 ) were washed in PBS and resuspended in 1 mL diluent C from the kit. The PKH26 was diluted to 4 μM in 1 mL diluent C. Cells were combined with dye, and the tube was inverted several times over 3 min. About 2 mL FBS was added to the tubes, and tubes were inverted continuously for 1 min. Cells were then transferred to 15-mL conical tubes with 4 mL phenol red-free of RPMI 1640 with 10% FBS and washed three times in the same medium. OTI CD8 + T (1 × 10 6 -1 × 10 7 ), CD8 + T, or CD19-targeted CAR CD8 + T cells (5 × 10 6 ) were washed twice in phenol red-free RPMI with 10% FBS, mixed with PKH26-labeled cancer cells (1 × 10 6 ) , and incubated at 37°C for 4 h. After incubation, 10 μL of a 5 μg/mL solution of 7-AAD was added to the cell suspension for 10 min on ice. Cells were evaluated on a FACSCanto (BD Biosciences), and data were analyzed with FlowJo software (Treestar).
Xenograft model
For the OVA-E0771 tumor model, the fourth mammary fat pads (murine mammary glands) of 8-week-old C57BL/6 female mice were orthotopically injected with 5 × 10 5 OVA-E0771 cells on day 0. Mice were conditioned with 5 Gy total body irradiation immediately before T-cell transfer. OTI CD8 + T (1 × 10 7 cells), OTI TG2-CD8 + T, or OTI TG2P-CD8 + T cells were injected into the tail vein on days 7, 10, and 13 after tumor inoculation. Animals were sacrificed 28 days after tumor injection, and tumors were weighed and imaged.
For analysis of the in vivo activity of TG2-loaded CD8 + T cells, OTI CD8 + T, OTI TG2-CD8 + T, or OTI TG2P-CD8 + T cells (1 × 10 7 ) were injected into the tail vein on day 14 after tumor inoculation. Two days later, animals were sacrificed, and tumor tissues were extracted. For immunofluorescence, tumor tissues were fixed in 4% paraformaldehyde for 2 h at room temperature, washed with PBS, and dehydrated in 30% sucrose until tumor tissues sunk. Tissues were then cryoprotected with Tissue-Tek OCT (Sakura Finetek, Torrance, CA), and 10 μm cryosections were mounted with Fluorescent Mounting Medium (Dako, Carpinteria, CA). Images were obtained using a 40×, NA 1.40 oil immersion objective on a laser-scanning confocal microscope (FV1000). To compare the amounts of tumor infiltrated CD8 + T cells (OTI CD8 + T (green) and OTI TG2-CD8 + T (green/red) or OTI TG2P-CD8 + T (red) cells, tumor tissues were homogenized in PBS, and cells were evaluated on a FACSCanto instrument (BD Biosciences). Data were analyzed with FlowJo software (Treestar).
For immunohistochemistry (IHC), the extracted tumor tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Tissue slices (5 μm) were incubated with anti-ICAM-1, anti-CD8T, anti-Ki67, anti-GZMB, and anti-INFγ antibodies or TdT-BiOTIn-dUTP mix (100 μl TdT buffer [30 mM Tris, pH 7.2, 140 mM sodium cacodylate, 1 mM cobalt chloride], 30 U TdT, and 0.5 μL BiOTIn-dUTP mix [Boehringer Mannheim, Indianapolis, IN]) followed by diaminobenzidine staining (Dako and R&D Systems), according to the manufacturer's instructions. TUNEL assays were performed using an In Situ Cell Death Detection kit, AP (Roche, Mannheim, Germany). Microscopy images were analyzed using ImmunoRatio (http://imtmicroscope.uta.fi/immunoratio) or recorded by a pathologist.
Establishment of human CD19-targeted CAR-T cells
Human CD8
+ T cells were purified from healthy donor blood samples using EasySep (StemCell Technologies). The purity of each population was confirmed to be more than 95% by flow cytometry. Before lentiviral transduction, isolated human CD8 + T cells were incubated in 2 µg/mL anti-OKT3/CD28-coated culture plates with 100 U/mL rIL-2 for 48 h. A total of 5 × 10 6 viral packaging cells (Plat-E; Cell Biolabs) were plated overnight in 10-cm 2 dishes. Lentiviral particles were generated by transfection with a lentiviral vector (CD19-targeted CAR viral plasmid, CellRapeutics TM E19828bbz; Creative Biolabs, NY) and packaging vector using Lipofectamine 2000 (Invitrogen). After 48 h, virus supernatants (1 mL) were harvested, mixed with 10 6 human CD8 + T cell blasts, incubated in 12-well plates with 8 μg/mL polybrene (Sigma) and 100 U/mL rIL-2. The transduced CD8 + T cells were maintained with fresh media with rIL-2 and expanded for 10-13 days.
Statistical analysis
Mean values were calculated using data taken from at least three independent experiments conducted on different days. Where significance testing was performed, unpaired Student's t tests and one-way analysis of variance tests were used. Differences between groups were considered significant when the P value was less than 0.05.
